The Hindu Business Line : Anti-Malaria vaccine trials

Avaccine being developed by the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi to prevent malaria will be entering phase I clinical trails in next six months, according to Mr M. K. Bhan, Secretary, Department of Biotechnology, Government of India. The vaccine, being developed with the funding from Bill & Milinda Gates Foundation, would prevent malaria caused by plasmodium vivax, Mr Bhan told newspersons here on Thursday. On the proposed Biotech Regulatory Authority, the official said the bill was awaiting Cabinet's approval to be tabled in the Parliament. Once operational, the Authority would replace the Genetic Engineering Approval Committee (GEAC), he added. - Our Bureau

More Stories on : Announcements | Pharmaceuticals | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Celestial Labs to change name

Aurobindo drug gets US nod

Anti-Malaria vaccine trials

BEML bags Rs 185-cr NCL order

Award for SECL

Tata Power to raise $300 m through bonds

Orbitech cuts stake in Polaris Software

Mahindra auto plant likely near Chennai

Feng Tay to increase capacity at its shoe-making unit

Pagaria Power to set up plant in Konkan

Funeral directors eye India to set up shop!

Rico strike ends; nine of 16 suspended workers rejoin

FIPB defers decision on EADS, L&T joint venture proposals

Phillips Carbon to shift to CBM as feedstock

BHEL bets on near doubling of orders in H2

RMoney CEO to join Spice as Group President

Wal-Mart scion meets PM